Migraine trials recruiting in Alabama

All Migraine trials nationally

Cities in Alabama

Recruiting trials in Alabama

• A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07674654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Mobile
• A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
  NCT06810505 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Alabama: Huntsville
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
  NCT05711394 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Alabama: Huntsville, Saraland
• A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
  NCT06625060 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Alabama: Birmingham, Huntsville
• A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07645924 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Alabama: Birmingham, Mobile
• A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
  NCT06602479 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Alabama: Birmingham, Huntsville
• Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
  NCT04748601 · Phase: Phase 4 · Ages: 6 Years to 11 Years · Sex: All (male and female) · Alabama: Birmingham
• Randomized Study in Children and Adolescents With Migraine: Acute Treatment
  NCT04649242 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Alabama: Birmingham
• Responding With Evidence and Access for Childhood Headaches
  NCT05889624 · Phase: Not applicable (e.g. observational or device study) · Ages: 10 Years to 17 Years · Sex: All (male and female) · Alabama: Birmingham
• Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
  NCT05125302 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Alabama: Huntsville, Saraland